BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update.

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis

SOMERSET, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2025 unaudited financial results and key corporate highlights.

BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs.

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts

New York, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Interpublic Group (NYSE: IPG), a global leader in marketing solutions, today announced a first-of-its-kind strategic partnership with Aaru, a cutting-edge AI and technology company specializing in predictive simulations for human behavior.

Former Nebraska State Senator Tony Fulton Re-Joins NioCorp Board After Serving as Nebraska's 22nd Tax Commissioner and Director of the Nebraska Department of Revenue CENTENNIAL, CO / ACCESS Newswire / August 11, 2025 / NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:NB) is pleased to announce that Tony Fulton has re-joined the Company's Board of Directors (the "Board"), filling a current vacancy.

TORONTO--(BUSINESS WIRE)--Americas Gold and Silver Corporation (TSX: USA) (NYSE American: USAS) (“Americas” or the “Company”), a growing North American precious metals producer, reports consolidated financial and operational results for the quarter ended June 30, 2025. This earnings release should be read in conjunction with the Company's Management's Discussion and Analysis, Financial Statements and Notes to Financial Statements for the corresponding period, which have been posted on the Ameri.

TORONTO--(BUSINESS WIRE)---- $LGO #cleanenergy--Largo Announces $6 Million Secured Loan to Support Working Capital.

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.

Successful completion of strategic reorganization, reducing debt by $1.15 billion. In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a “Successor” period from 6/25/25 to 6/30/25

NASDAQ:EU TSXV:EU www.encoreuranium.com DALLAS , Aug. 11, 2025 /PRNewswire/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the "Company" or "enCore"), America's Clean Energy Company™, today announced its financial and operational results for the six months ended June 30, 2025. Highlights for three months ended June 30, 2025 include: Three months ended June 30, 2025 net loss per share $(0.03) versus $(0.12) in same period 2024; Sale (delivery) into contract of 60,000 pounds of uranium ("U3O8") at a sales price of $61.07 and a weighted average cost of $42.23; Three months ended June 30 U3O8 extraction of 203,798 pounds, an …

Total revenue of $25.7 million, up 6% sequentially 4 licensing deals signed for NeuPro NPUs, marking pivotal moment for Ceva's AI business 2 strategic automotive IP agreements secured with U.S. companies for V2X and 4D radar Ceva-powered device shipments of 488 million units in the quarter, including record cellular IoT and Wi-Fi 6 shipments Surpassed 20 billion Ceva-powered device milestone, underscoring technology leadership and deep industry partnerships for more than two decades Repurchased 300,000 shares of Ceva stock for approximately $6.2 million during the quarter ROCKVILLE, Md. , Aug. 11, 2025 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor …

ANCHORAGE, Alaska , Aug. 11, 2025 /PRNewswire/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to provide an update with respect to discussions with representatives from the State of Alaska and Matanuska-Susitna Borough ("MSB") regarding plans to advance the West Susitna Access Project ("WSAP"). The Company is very pleased to report, based on discussions to date, continued strong support at all levels of government for the Whistler Gold-Copper Project ("Whistler" or the "Project") and that all critical elements of the WSAP, which will connect Whistler with existing highway, rail, power and port infrastructure, are moving …

ADDISON, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announces that CECO management will participate at the following investor conferences:

Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned …

Quarterly services revenue jumped by 6% sequentially to $86.5 million, increasing from $81.8 million in Q4'25. Total revenue grew by 38% year-over-year to $104.1million driven by strength in services revenue, which increased to a record high of 83% of total revenue.

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyi.